Vitamin D and Acute Respiratory Infections—the PODA Trial

John F. Aloia, Shahidul Islam, and Mageda Mikhail
NYU Long Island School of Medicine, Mineola, New York

Background. There is considerable heterogeneity in clinical trials examining the role of vitamin D in the prevention of acute respiratory infections (ARIs).

Methods. The primary aim of the Physical Performance, Osteoporosis, and Vitamin D in Older African-American Women (PODA) trial was the prevention of bone loss and decline in physical performance. A questionnaire about ARIs was administered every 3 months for 3 years to 260 black American women in a double-blind randomized clinical trial that had a placebo group and a vitamin D supplementation group. The serum 25(OH)D level was maintained >30 ng/mL in the vitamin D group.

Results. Serum 25(OH)D was maintained >30 ng/mL in 90% of the active group, whereas levels approximated those associated with the recommended dietary allowance (20 ng/mL) in the placebo group. There was no difference in occurrence of ARIs in the treatment group vs the placebo group. ARIs were not related to total or free 25(OH)D, which were measured at baseline and annually for 36 months.

Conclusions. Vitamin D supplementation sufficient to maintain serum 25(OH)D >30 ng/mL does not prevent ARIs in older African American women.

ClinicalTrials.gov Registration Number. NCT01153568.

Keywords. acute respiratory infection; osteoporosis; vitamin D; vitamin D metabolites.
from each participant, and the trial was approved by the Winthrop Institutional Review Board and monitored by a Data Safety Monitoring Board appointed by the National Institute of Aging. The trial was registered at www.clinicaltrials.gov as NCT011533568.

Healthy participants were recruited from the Long Island community by direct mail, email to hospital employees, and presentations at black churches and events. The study was conducted in an ambulatory Clinical Research Center of an academic health center. After screening, those who consented and qualified were randomly allocated to 1 of 2 groups: vitamin D supplementation or placebo. Inclusion criteria were healthy ambulatory women who were self-declared as black Americans, with serum 25(OH)D >8 ng/mL and <26 ng/mL. Participants returned for follow-up visits every 3 months for 36 months. A questionnaire concerning upper respiratory infections was administered by the research coordinator at each visit.

Fasting blood samples were collected at baseline and at 3-monthly visits. Serum samples for measurement of 25OHHD and 1,25(OH)2D at baseline and annually were analyzed by the Department of Laboratory Medicine at the University of Washington (Seattle, WA) using liquid chromatography–tandem mass spectrometry with deuterated internal standards for each analyte [32]. Concentrations of 25(OH)D were standardized to National Institute of Standards and Technology SRM 972a [33]. Serum-free 25OHHD was directly measured using enzyme-linked immunosorbent assay based on a 2-step immunoassay procedure (Future Diagnostics, Wijchen, the Netherlands), as previously described [34, 35]. Markers of bone turnover and parathyroid hormone (PTH) levels were measured in serum at baseline and at 6-month intervals. Intact PTH was measured by the Immulite 2000 Analyzer assay (Diagnostic Products Corporation, Los Angeles, CA; interassay CV: 1.34%).

Statistical Methods

Block randomization with a block size of 4 was performed at baseline using a computer-generated (SAS Proc Plan; SAS Institute, Inc., Cary, NC) randomization list. Subjects were assigned to 1 of 2 groups: vitamin D3 supplementation or placebo. Any participants who were randomized and received at least 1 dose of study medication were included in the intention-to-treat (ITT) population, and primary analysis was performed according to the ITT principle. In the original study design, power was determined based on previous studies and a differential bone mineral density rate of change of ≥0.18% per year.

Descriptive statistics were generated and presented as mean ± standard deviation or median (interquartile range) for continuous variables and frequency (percentage) for the categorical variables. Normality of distribution of clinical variables and laboratory markers was examined using visual inspection of histograms and the Kolmogorov-Smirnov test. Between-group differences for each continuous variable were examined using the nonparametric Wilcoxon rank-sum test for non-normally distributed variables and the 2 independent-samples t test for normally distributed variables. Variables were checked for outliers, and analyses were performed with and without outliers, but output remained similar, so full data were used. The Fisher exact test was used to compare categorical variables between groups.

ARI data were gathered from the following question: “How many times did you have a cold or flu?” Answer choices were “none,” “1 to 2,” or “3 to 4” times. Data were collected at each 3-month visit. There were only a few subjects with 3 to 4 events (n = 9 events). Therefore, the “1 to 2” and “3 to 4” categories were combined. Essentially, a variable was re-coded as with 1 = had ARI since last visit and 0 = did not have ARI since the last visit.

The difference in ARI rate between treatment groups over time was evaluated using a repeated-measures mixed-effects logistic regression model. A random subject-specific intercept and an unstructured correlation structure were used to account for within-subject correlation between ARI rates over-time. Model fit was assessed using fit statistics such as AIC and Pearson chi-square/degrees of freedom. Associations of ARI with 25(OH)D, Free25(OH)D, 1,25(OH)2D, PTH, serum creatinine, physical activity (measured as caloric expenditure), over-time were also evaluated using mixed-effects logistic regression models. All calculations were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, NC). Results were considered statistically significant at a P value of <.05.

RESULTS

Baseline Demographics, Laboratory Studies, and Adherence

The average age was 68.2 years, and the BMI was 30 kg/m² (Table 1). There were no statistically significant differences in baseline characteristics between assigned groups. The mean dose of vitamin D3 in the active arm was 3490 (±1465) IU/d.

Values (mean ± SD) for 25(OH)D at 12, 24, and 36 months in the active group were 43 ± 9.1, 46 ± 11.0, and 47 ± 11.2 ng/mL, respectively. Corresponding values for the placebo group were 19 ± 8.0, 20 ± 7.9, and 21 ± 10.0 ng/mL. Ninety percent of the active group maintained serum 25(OH)D above the 30-ng/mL threshold. Serum calcitriol increased by 10% at 36 months in the treatment group. Serum calcium did not change in either group. Overall compliance from pill count was 85% for the entire study.

Flow Diagram

A flow diagram for the study is given in Figure 1 [30]. The first participant was randomized on December 8, 2010, and the last 36-month visit was June 13, 2016. In the placebo group, there were 41 dropouts. In the vitamin D group, there were 33 dropouts; 1 subject had primary hyperparathyroidism. One subject in the placebo group died due to cardiorespiratory failure. Eighty-nine subjects in the placebo group and 95 subjects in the vitamin D group completed the 36-month study.
Table 1. Demographics and Baseline Characteristics

| Demographics and behavioral | Active (n = 130) | Placebo (n = 130) | Overall (n = 260) | P |
|-----------------------------|-----------------|------------------|------------------|---|
| Age, y<sup>b</sup>          | 67.8 (65.1–71.5)| 69.0 (65.4–73.4) | 68.2 (65.4–72.5) | .251 |
| BMI, kg/m<sup>2</sup><sup>b</sup> | 30.2 (26.4–34.6) | 30.0 (26.8–33.9) | 30.1 (26.6–34.1) | .867 |
| Calcium intake, mg<sup>b</sup> | 842.0 (600–1142) | 826.5 (628.0–1185) | 828.0 (614.0–1164) | .857 |
| Laboratory                  |                 |                  |                  |    |
| 25(OH)D<sub>3</sub>, ng/mL | 21.5 ± 6.5      | 22.2 ± 6.9       | 21.8 ± 6.7       | .352 |
| PTH, pg/mL<sup>b</sup>      | 56.1 (41.0–73.6)| 56.4 (39.5–73.8) | 56.2 (39.8–73.8) | .977 |
| Serum Ca, mg/dL<sup>b</sup> | 9.5 (9.3–9.8)   | 9.5 (9.3–9.8)    | 9.5 (9.3–9.8)    | .943 |
| Serum Cr, mg/dL<sup>b</sup> | 0.8 (0.7–0.9)   | 0.7 (0.6–0.9)    | 0.8 (0.6–0.9)    | .472 |
| Free 25(OH)ID, pg/mL        | 4.7 ± 1.2       | 4.8 ± 1.3        | 4.7 ± 1.3        | .565 |
| 1, 25(OH)<sub>2</sub>D<sub>3</sub>, pg/mL | 52.4 ± 13.7 | 52.6 ± 15.4 | 52.5 ± 14.6 | .926 |

Normally distributed variables are presented as mean ± SD, and non-normally distributed variables are presented as median (IQR). Abbreviations: BMI, body mass index; IQR, interquartile range.

<sup>a</sup>For continuous data, P values are from a Wilcoxon rank-sum test for non-normally distributed variables and a 2 independent-samples t test for normally distributed variables. For categorical variables, P values are from the Fisher exact test.

<sup>b</sup>Non-normally distributed.

Figure 1. Flow diagram for the study. Two hundred fifteen of the 365 exclusions were due to having a high 25(OH)D level. In both the placebo group and vitamin D group, none of the dropouts were due to a gastrointestinal complaint. One dropout in the vitamin D group represents a subject found to have primary hyperparathyroidism at the 3-month visit. Dropouts designated as “other” were due to relocation out of the state or country, general health issues, and 1 subject who was withdrawn by the principal investigator after having gastric bypass surgery, as this would affect vitamin D absorption.
Efficacy of Treatment on ARI

At 3 months, 24 (21.6%) patients in the vitamin D group reported that they had had an ARI since randomization compared with 25 (21.4%) in the placebo group. At the end of 3 years, both groups reported 18% ARI since their last visit. Overall, the ARI rate did not change significantly from baseline (slope, –0.0081; \( P = .232 \) for time effect), and it was not different between treatment groups over time (nonsignificant interaction between group and time; slope, 0.00313; \( P = .775 \)) (Figure 2). A Pearson chi-square/degrees of freedom value of 0.81 (close to 1) for our model assures a good fit.

ARI, Vitamin D, and Other Biomarkers

We examined the relationship between ARI and 25OHD3 levels in 2 different ways: (1) using 25OHD levels as a continuous measurement for the entire sample (\( P \) value for time and 25(OH)D interaction = .495) and (2) categorizing 25OHD into tertiles (0.3–20.3, 20.3–33.6, and 33.6–73.5 ng/mL). For the tertiles, a model was developed using the categorical tertile indicator and time (\( P \) value for the interaction term = .963). In addition, a model was developed for each tertile using time-dependent 25OHD levels (Table 3). Although we observed a larger inverse effect of 25(OH)D3 on ARI in the lower tertile than the other tertiles, it did not reach statistical significance (slope [SE], –0.2826 [0.1496]; \( P = .062 \)). We found no other associations between ARI and 25OHD3 levels over time. Similarly, we evaluated the relationship between ARI and free 25(OH)D and found no association (\( P \) value for the time and free 25(OH)D interaction term = .893). The tertile values of free 25(OH)D were (1.5–4.7, 4.7–7.3, and 7.3–23.8 pg/mL).

A subgroup analysis was conducted by restricting the data set to winter months only (December through March). Two separate models were considered to examine the relationships between ARI and vitamin D over time. The first model considered group, time and the 2-way interaction between group and time. The second model considered 25OHD3 levels, time, and the interaction term between 25OHD and time. We found no association between vitamin D supplementation and ARI in either model (\( P \) value for the group × time interaction = .831 and for 25OHD × time interaction = .419).

Additionally, we have assessed the relationships of ARI with 1,25(OH)2D3, PTH, serum creatinine, physical activity (caloric expenditure), grip strength, SPPB, and 6-minute walk test, percent body fat, and BMI “over time”. None of these factors were associated with ARI in repeated-measures analyses (Table 2).

DISCUSSION

Our findings are similar to those in our previously reported randomized clinical trial (RCT): We found no evidence to support vitamin D supplementation to levels higher than the RDA-associated 25(OH)D level of 20 ng/mL in prevention of ARIs [3]. This is consistent with 8 meta-analyses of the influence of vitamin D on the occurrence of ARIs [23, 36–42] since 2012. Although 3 found a significant positive effect, 5 found no significant effects. Significant heterogeneity was noted between the included trials [21].

![Figure 2](image-url)  
Figure 2. Predicted probability of acute respiratory infections over time estimated by the mixed-effects logistic regression model.
Table 2. Mixed-Effects Logistic Regression Models for ARI Using Vitamin D and Other Biomarkers

| Models for ARI | Estimate (Standard Error) | P   |
|---------------|---------------------------|-----|
| 25(OH)D, ng/mL | -0.0085 (0.028)           | .747|
| Time, mo      | 0.0126 (0.020)            | .525|
| Time*25(OH)D  | 0.0005 (0.001)            | .495|
| Free25(OH)D, pg/mL | 0.0085 (0.025)           | .734|
| Time, mo      | 0.0284 (0.073)            | .698|
| Time*Free25(OH)D | -0.0004 (0.003)           | .989|
| 1,25(OH)2D, pg/mL | -0.0022 (0.0018)           | .500|
| Time, mo      | 0.0001 (0.001)            | .938|
| 1,25(OH)2D, pg/mL | 0.0010 (0.038)           | .771|
| Time, mo      | 0.0122 (0.018)            | .500|
| Time*1,25(OH)2D | -0.0001 (0.001)           | .938|
| PTH, pg/mL    | 0.0128 (0.026)            | .632|
| PTH, pg/mL    | 0.0007 (0.014)            | .96 |
| Time*PTH      | 0.0001 (0.001)            | .807|

Abbreviation: ARI, acute respiratory infection.

Most recently, Martineau et al. [43] performed a meta-analysis using individual participant data from 25 randomized controlled trials (10,933 participants). They found a statistically significant reduction from vitamin D supplementation in the risk of having at least 1 ARI. Reasons for heterogeneity between trials were explored by subgroup analyses. There was a strong protective effect in those with 25(OH)D levels <10 ng/mL and no significant effect in those with serum 25(OH)D >10 ng/mL. There was also a protective effect in children (1–16 years old). They also found that whereas daily or weekly doses were protective, bolus doses were not.

In an accompanying editorial, Bolland and Avenell [21] questioned the significance of these beneficial findings, pointing out that there was only an absolute reduction from 42% to 40% in those having at least 1 acute respiratory infection. Our study was consistent with their conclusion that there is not sufficient evidence at present to recommend vitamin D to prevent ARIs. Whether race is a factor in the prevention of ARIs in the Martineau et al. [43] study could not be ascertained because many studies did not identify race.

Our population, with a mean baseline 25(OH)D approximating the RDA, showed no benefit in raising levels to the Endocrine Society Guidelines (20 ng/mL). We have previously reported that we found no benefit of raising 25(OH)D levels >30 ng/mL on bone loss, physical performance, falls, or cognition [28, 29, 31, 43]. We could not find evidence for an effect on ARIs in the current study. However, our patient population may have been too small to detect an effect. Several large studies will soon be reported that may resolve the issue of sample size [44, 45]. Studies in progress, however, may not have sufficient subjects with very low baseline serum 25(OH)D levels. A recent RCT in Vietnamese children found a benefit of vitamin D supplementation in preventing noninfluenza respiratory infection [46]. It has been speculated that total serum 25(OH)D might not indicate a positive effect on ARIs whereas free 25(OH)D might. In the current study, free 25(OH)D was measured using a direct assay. There was no protective effect with either total serum 25(OH)D or free 25(OH)D. In addition, there was no protective effect of serum calcitriol.

We acknowledge several weaknesses in our study. Its findings cannot be extrapolated to men, other racial backgrounds, vitamin D deficiency, other ages and children, or institutionalized individuals. There was no testing for flu or other medically diagnosed influenza-like illness. It is likely that ARI events would have been captured better if real-time techniques were used rather than a 3-month recall. However, faulty recall should apply evenly to both treatment groups, and participants were high functioning. The strengths of our study include using a healthy, community-dwelling population that was studied for 3 years. Serum 25(OH)D was measured using standardized assay methods, and free 25(OH)D was measured as well.

In conclusion, in older healthy black women, we found no difference in self-reported ARIs by maintaining serum 25(OH)D above the current associated RDA value.

Acknowledgment

Financial support. Funding was provided by National Institute of Aging grant #R01-AG032440-01A2.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134:1129–40.
2. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect 2007; 135:1095–6; author reply 1097–8.

Table 3. Regression Models for ARI Using Time-Dependent 25(OH)D3 Values as a Covariate

| Models for ARI | Estimate (Standard Error) | P   |
|---------------|---------------------------|-----|
| Tertile 1: 25(OH)D3 range 0.3–20.3 ng/mL | -0.1274 (0.090) | .16 |
| Time, mo      | -0.2826 (0.1496)          | .062|
| Time*25(OH)D3 | 0.0102 (0.0063)           | .111|
| Tertile 2: 25(OH)D3 range 20.3–33.6 ng/mL | -0.2829 (0.1836) | .129|
| Time, mo      | -0.1659 (0.1648)          | .318|
| Time*25(OH)D3 | 0.0105 (0.0067)           | .122|
| Tertile 3: 25(OH)D3 range 33.7–73.5 ng/mL | -0.0428 (0.0602) | .673|
| Time, mo      | -0.0464 (0.0602)          | .442|
| Time*25(OH)D3 | 0.0012 (0.0022)           | .584|

Abbreviation: ARI, acute respiratory infection.

Estimates are from mixed-effects logistic regression models.
3. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect 2009; 1–9.

4. Uraghima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010; 91:1255–60.

5. Laaksi I, Ruohola J, Mattila V, et al. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blind trial among young Finnish men. J Infect Dis 2010; 202:809–14.

6. Camargo CA Jr, Gamma D, Frazier AL, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics 2012; 130:e561–7.

7. Murdoc DR, SS, Chambers ST, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012; 308:1333–9.

8. Bergman P, Norlin AC, Hansen S, et al. Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. BMJ Open 2012; 2:e001663.

9. Rees JR, Hendricks K, Barry EL, et al. Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial. Clin Infect Dis 2013; 57:1384–92.

10. Tran B, Armstrong BK, Ebeling PR, et al. Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. Am J Clin Nutr 2014; 99:55–61.

11. Goodall EC, Granados AC, Linstra K, et al. Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial. BMC Infect Dis 2014; 14:273.

12. Uraghima M, Mezawa H, Noya M, Camargo CA Jr. Effects of vitamin D supplements on influenza A illness during the 2009 H1N1 pandemic: a randomized controlled trial. Food Funct 2014; 5:2365–70.

13. Grant CC, Kaur S, Waymouth E, et al. Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomized controlled trial. Acta Paediatr 2015; 104:396–404.

14. Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDICO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2015; 3:120–30.

15. Martineau AR, Hanifa Y, Witt KD, et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax 2015; 70:953–60.

16. Martineau AR, MacLaughlin BD, Hooper RL, et al. Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDaAsthm). Thorax 2015; 70:451–7.

17. Simpson S Jr, Van der Mei I, Stewart N, Blizard L, Tettey P, Taylor B. Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT. BMC Nutr 2015; 1:7.

18. Dubnov-Raz G, Birnbaum M, Hemila H, et al. Vitamin D supplementation and upper respiratory tract infections in adolescent swimmers: a randomized controlled trial. Pediatr Exerc Sci 2015; 27:113–9.

19. Denlinger LC, King TS, Cardet JC, et al; NHLBI AsthmaNet Investigators. Vitamin D supplementation and the risk of colds in patients with asthma. Am J Respir Crit Care Med 2016; 193:634–41.

20. Ginde AA, Blatchford P, Breese K, et al. High-dose monthly vitamin D for prevention of acute respiratory infection in older long-term care residents: a randomized clinical trial. J Am Geriatr Soc 2016; 64:496–503.

21. Bolland MJ, Avenell A. Do vitamin D supplements help prevent respiratory tract infections? BMJ 2017; 356:j356.

22. Autier P, Mullie P, Macacu A, et al. Effect of vitamin D supplementation on nonskeletal disorders: a systematic review of meta-analyses and randomised trials. Lancet Diabetes Endocrinol 2017; 5:986–1004.

23. Xiao L, Xing C, Yang Z, et al. Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomised controlled trials. Br J Nutr 2015; 114:1026–34.

24. Dhillawal R, Mikhail M, Usora G, et al. The relationship of physical performance and osteoporosis prevention with vitamin D in older African Americans (PODA). Contemp Clin Trials 2018; 65:39–45.

25. Ross AC, Taylor CL, Yakine AL, et al., eds., National Academy Press, Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2011.

26. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012; 97:1153–8.

27. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012; 97:1146–52.

28. Aloia JF, Mikhail M, Fazzari M, et al. Physical performance and vitamin D in elderly black women—the PODA randomized clinical trial. J Clin Endocrinol Metab 2019; 104:1441–8.

29. Ouwusu JE, Islam S, Katumulawwa SS, et al. Cognition and vitamin D in older African-American women—physical performance and osteoporosis prevention with vitamin D in older African Americans trial and dementia. J Am Geriatr Soc 2019; 67:81–6.

30. Aloia JF, Rubinova R, Fazzari M, et al. Vitamin D and falls in older African American women: the PODA randomized clinical trial. J Am Geriatr Soc 2019; 67:1043–9.

31. Aloia J, Fazzari M, Islam S, et al. Vitamin D supplementation in elderly black women does not prevent bone loss: a randomized controlled trial. J Bone Miner Res 2018; 33:1916–22.

32. Laha TJ, Strathmann FG, Wang Z, et al. Characterizing antibody cross-reactivity for immunofluorescence purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry. Clin Chem 2012; 58:1711–6.

33. Hoofnagle AN, Laha TJ, Deo HB. Recalibration of 24,25-dihydroxyvitamin D3 results based on NIST standard reference material 972a. Am J Kidney Dis 2016; 67:812–3.

34. Schwartz JB, Lai J, Lizziola B, et al. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. J Clin Endocrinol Metab 2019; 94:1631–7.

35. Aloia J, Dhailwal R, Mikhail M, et al. Free 25(OH)D and calcium absorption, PTH, and markers of bone turnover. J Clin Endocrinol Metab 2015; 100:4140–5.

36. Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: a systematic review and meta-analysis. J Pharmcol Pharmacother 2012; 3:300–3.

37. Bergman P, Lindh AU, Bjorkhem-Bergman L, Lindh JD. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2013; 8:e65835.

38. Mao S, Huang S. Vitamin D supplementation and risk of respiratory tract infections: a meta-analysis of randomized controlled trials. Scand J Infect Dis 2013; 45:696–702.

39. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol 2013; 136:321–9.

40. Ahn J, Lee D, Kim K. Vitamin D and risk of respiratory tract infections in children: a systematic review and meta-analysis of randomized controlled trials. Pediatr Infect Vaccine 2016; 23:109–16.

41. Jat K. Vitamin D and lower respiratory tract infection in children: a systematic review and meta-analysis of randomized controlled trials. Clin Pulm Med 2016; 23:157–62.

42. Vuichard Gysin D, Dao D, Gysin CM, et al. Effect of vitamin D3 supplementation on respiratory tract infections in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2016; 11:e0162996.

43. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356:j356.

44. Scragg R, Waayer D, Stewart AW, et al. The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. J Steroid Biochem Mol Biol 2016; 164:318–25.

45. Manson JE, Balsusk SS, Lee IM, et al. The ViTamin D and Omega-3 Trial (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012; 35:159–71.

46. Loeb M, Dang AD, Thiem VD, et al. Effect of vitamin D supplementation to reduce respiratory infections in children and adolescents in Vietnam: a randomized controlled trial. Influenza Other Respir Viruses 2019; 13:176–83.